Insider · CIK 0001863429
Kathleen B. Lynch
Files at KODK (EASTMAN KODAK CO), MRP (Millrose Properties, Inc.). First filing Nov 25, 2025, latest Nov 25, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MRP: Millrose Properties, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Millrose Properties, Inc. | $59k 1,860 shares | +24% | +56% from low-10% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | MRP Millrose Properties, Inc. | AGrant or award Class A Common Stock | +6,451 | $0.00 | $0 | 15,961 | Dec 12, 2025 |
| Nov 24, 2025 | MRP Millrose Properties, Inc. | POpen-market purchase Class A Common Stock | +1,860 | $31.74 | $59k | 9,510 | Nov 25, 2025 |
| May 20, 2025 | KODK EASTMAN KODAK CO | DDisposition to issuer Restricted Stock Unitsderivative | -19,921 | $0.00 | $0 | 0 | May 22, 2025 |
| May 20, 2025 | KODK EASTMAN KODAK CO | AGrant or award Phantom Stockderivative | +19,921 | $0.00 | $0 | 65,361 | May 22, 2025 |
| May 21, 2025 | KODK EASTMAN KODAK CO | AGrant or award Restricted Stock Unitsderivative | +16,393 | $0.00 | $0 | 16,393 | May 22, 2025 |
| May 19, 2025 | MRP Millrose Properties, Inc. | AGrant or award Class A Common Stock | +1,990 | $28.36 | $56k | 7,650 | May 20, 2025 |
| Apr 3, 2025 | MRP Millrose Properties, Inc. | AGrant or award Class A Common Stock | +5,660 | $0.00 | $0 | 5,660 | Apr 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.